*Refresh the page if the below document does not appear.
A 100% spin-off of Sandoz would result in the creation of the top European generics company, a world leader in biosimilars, and a more narrowly focused Novartis. This separation would be in the best interests of shareholders, according to the Sandoz strategic review.
Bayer announced that it has launched Kerendia, a medication for the treatment of chronic kidney disease associated with diabetes. The medication is recommended for people with type 2 diabetes and chronic kidney disease.
Two important anti-diabetic medications, Linagliptin and Sitagliptin, have fixed prices set by India’s drug pricing authority. The National Pharmaceutical Pricing Authority has set retail prices for 45 drug formulations, including the two anti-diabetic medications.
USFDA has given final approval to Aurobindo Pharma Limited’s wholly-owned subsidiary, Eugia Pharma Specialties Limited, to manufacture and market Medroxyprogesterone Acetate injectable suspension in a single dose vial in the US market.
The drug Lynparza (olaparib), manufactured by AstraZeneca and MSD, has received approval in Japan for the adjuvant treatment of patients with early-stage BRCA-mutated, HER2-negative breast cancer who are at high risk of recurrence.
Lupin Limited has signed an exclusive licencing agreement with I’rom Group Co. Ltd, a Japanese pharmaceutical company and as part of the Agreement’s terms, will exclusively register, distribute, and market the biosimilar Denosumab in Japan.
Teclistamab, a BCMAxCD3 bispecific antibody
from Johnson & Johnson, has received its first
global approval in Europe for the treatment of
multiple myeloma following at least three prior
If you don’t already have an account click the button below to create your account.Create New Account
Please update your profile to keep using the website